免疫抑制剂在临床上多用于防治免疫异常所致的疾病，如抗器官移植排斥反应和自身免疫性疾病。然而，免疫抑制剂在临床应用中具有明显的肝脏不良反应，临床上多采用高效低毒的新型免疫抑制剂、免疫抑制剂间联合用药和联合保肝药等方式，以减少其肝脏不良反应。对糖皮质激素、环孢素、他克莫司、硫唑嘌呤、环磷酰胺、雷公藤多苷和来氟米特等常用的免疫抑制剂所致肝损伤的研究进展进行综述，以期为免疫抑制剂在临床上的安全用药提供参考依据。

Immunosuppressant is widely used to prevent and cure diseases caused by immune abnormalities, such as organ transplant rejection and autoimmune diseases. However, immunosuppressive agents have obvious hepatic adverse reactions in clinical application. In clinical practice, new immunosuppressants with high efficiency and low toxicity, combined use of immunosuppressants and combined hepatoprotective drugs are often used to reduce liver adverse reactions. In this paper, the research progress of liver injury induced by immunosuppressants such as glucocorticoid, cyclosporine, tacrolimus, azathioprine, cyclophosphamide, tripterygium glycosides and lefluride was reviewed, which provided reference for the safe use of immunosuppressants in clinical practice.

R979.5，R969.3

国家自然科学基金面上资助项目(82074114,81973562)